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comprehensive summary of massive amounts of available
randomised controlled trial (RCT) data. The question is how
carotid artery stenting (CAS) compares to carotid endarter-
ectomy (CEA) in both asymptomatic (n ¼ 3467) and symp-
tomatic (n ¼ 5797) patients.1 Typically in surgery, the
problem is a lack of good quality randomised studies. In ca-
rotid disease, the problem is how to master and interpret the
abundant data available. Important deficiencies like the lack
of operator and patient blinding, and no randomisation over
time, leave room to question some results. Indeed, interna-
tionally, the same data are interpreted in various ways.2,3
Regarding symptoms, some refuse to intervene when the
patient is asymptomatic, whereas some encourage their
asymptomatic patients to be treated and end up in a situa-
tion where most of their patients have a limited theoretical
benefit from the procedure.4 Until relatively recently, the
durability of CAS has been questioned. Today, and once more
underlined by the authors, it seems accepted that if the
patient does not get a peri-procedural complication, CAS is a
durable procedure despite some restenosis, until at least 10
years, which is long enough for many of our patients.
Compared with many other open surgical procedures CEA
may be seen as a fairly small and straightforward procedure.
However, CAS with just a puncture to the groin has obvious
benefits. Thus, the justification to continue CEA arises from a
smaller peri-procedural risk ofmajor complications in the very
patients for whom invasive treatment is most beneficial:
symptomatic patients with recent (hemispheric) symptoms.
Batchelder et al.1 have once more shown that the operators
continuing to perform CAS for risky patients have to be
certain that they can perform it safer than in RCTs.Many claim
to achieve that, but few have actually demonstrated it in an
unbiased manner for a significant number of patients.
All who have seen many carotid plaques know that the
variation in them is an important factor and one that has
probably had an impact on the results of the RCTs. Some
plaques host a soft liquid core that may run freely into the
lumen irrespective of the size of the holes in the stent. Others
seem solid and stable. When operating soon after the index
event we frequently encounter fresh, unstable thrombi andDOI of original article: https://doi.org/10.1016/j.ejvs.2019.06.003
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https://doi.org/10.1016/j.ejvs.2019.07.003feel that anymanipulation could dislodge it, making clamping
the artery prior to manipulation an appealing solution. Oc-
casionally, fresh looking thrombus is present in asymptom-
atic patients as well, adding to the confusion.
A hot topic that was not addressed in this review owing
to a lack of RCTs is transcarotid artery revascularisation
(TCAR) flow reversal stenting, which is thought to overcome
many of the embolic problems. TCAR has shown superior
results to transfemoral CAS in mainly asymptomatic non-
randomised cohorts and a 3.7% transient ischaemic
attack/stroke/death rate in symptomatic ones.5 It should be
remembered that there is a strong economic interest in
selling the expensive device and large scale unbiased
studies with CEA as an option should be performed prior to
routine adoption of this appealing technique.
For me, the most important question remains: What
should we do in order to prevent as many strokes as
possible? The answer is simple: do not touch the patients
that do not need a procedure, intervene promptly when
there is a clear need, and perform the procedure without
complications and with a long lasting result. Batchelder
et al.1 have made the answers to these questions a bit more
clear and give an answer to many more detailed questions,
for which we need to thank them. However, many questions
remain, before which we need to remain humble, read the
details, and stick to practices that benefit our patients and
not our egos or bank accounts.REFERENCES
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